Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
1.120
-0.060 (-5.08%)
At close: Apr 15, 2025, 4:00 PM
1.092
-0.029 (-2.54%)
After-hours: Apr 15, 2025, 7:59 PM EDT
Aclaris Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Aclaris Therapeutics stock have an average target of 11.67, with a low estimate of 7.00 and a high estimate of 20. The average target predicts an increase of 941.96% from the current stock price of 1.12.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 7, 2025.
Analyst Ratings
The average analyst rating for Aclaris Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 4 | 4 |
| Hold | 2 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Mar 18, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $15 | Buy | Initiates | $15 | +1,239.29% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $20 | Hold → Strong Buy | Upgrades | $20 | +1,685.71% | Dec 23, 2024 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $2 → $7 | Hold → Buy | Upgrades | $2 → $7 | +525.00% | Nov 19, 2024 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $2 → $7 | Hold → Strong Buy | Upgrades | $2 → $7 | +525.00% | Nov 19, 2024 |
Financial Forecast
Revenue This Year
5.30M
from 18.72M
Decreased by -71.67%
Revenue Next Year
27.90M
from 5.30M
Increased by 425.96%
EPS This Year
-0.50
from -1.71
EPS Next Year
-0.76
from -0.50
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.2M | 46.9M | 51.5M | ||
| Avg | 5.3M | 27.9M | 22.7M | ||
| Low | 2.5M | 9.8M | 7.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -40.0% | 784.9% | 84.4% | ||
| Avg | -71.7% | 426.0% | -18.7% | ||
| Low | -86.4% | 84.8% | -73.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.14 | -0.67 | -0.82 | ||
| Avg | -0.50 | -0.76 | -0.91 | ||
| Low | -0.63 | -0.85 | -1.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.